Beyond anticoagulation: Statin therapy and 90-day mortality after breakthrough ischemic stroke in atrial fibrillation
Jenseits der Antikoagulation: Statintherapie und 90-Tage-Mortalität nach Durchbruch-Ischämischem Schlaganfall bei Vorhofflimmern
Therapeutic Advances in Neurological Disorders · 2026-11 · 19
DOI: 10.1177/17562864261493716 ↗Auf einen Blick
Bei 1.442 Patient:innen mit Vorhofflimmern und ischämischem Schlaganfall trotz oraler Antikoagulation war Statintherapie bei Entlassung mit geringerer 90-Tage-Gesamtmortalität verbunden.
Fragestellung
Ist Statintherapie bei Entlassung mit 90-Tage-Gesamtsterblichkeit bei Patient:innen mit Vorhofflimmern und ischämischem Schlaganfall trotz oraler Antikoagulation assoziiert?
Methode
Multizentrische, retrospektive Beobachtungskohorte in der ASPERA-R-Initiative; Erwachsene mit IS unter kontinuierlicher oraler Antikoagulation für AF, Februar 2020 bis Februar 2025.
Ergebnisse
1.016/1.442 (70,5 %) erhielten Statine. 90-Tage-Mortalität: 9,6 % vs. 19,2 %; HR 0,55 (95 %-KI 0,39–0,79). Der vaskuläre Kompositendpunkt war grenzwertig assoziiert; Blutungen selten.
Einschränkungen
Beobachtungsdesign; die Autoren bezeichnen die Befunde als hypothesengenerierend.
Schlussfolgerung der Autor:innen
Bei AF-Patient:innen mit IS trotz oraler Antikoagulation war Statintherapie bei Entlassung mit geringerer 90-Tage-Gesamtmortalität verbunden, ohne mehr kurzfristige Blutungen.
Kernaussagen
- Statine bei Entlassung: 9,6 % vs. 19,2 % 90-Tage-Mortalität
- HR 0,55 (95 %-KI 0,39–0,79)
- Kein Unterschied bei moderaten/schweren Blutungen und ICH
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Neurological Disorders, online erschienen am 03.11.2026. Verfasst von Giovanni Merlino und 39 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Secondary stroke prevention in patients with atrial fibrillation (AF) who experience an ischemic stroke (IS) despite oral anticoagulation remains challenging, and strategies have focused on antithrombotic optimization or left atrial appendage occlusion. Adjunctive statin therapy might reduce early vascular risk and mortality in this high-risk population.
Objectives
To evaluate the association between statin therapy at hospital discharge and 90-day all-cause death (primary outcome) in patients with AF experiencing IS despite oral anticoagulation.
Design
Multicenter, retrospective, observational cohort study within the ASPERA-R initiative.
Methods
Consecutive adults admitted between February 2020 and February 2025 with IS occurring during continuous oral anticoagulation for AF were included. Time-to-event analyses were landmarked at discharge to minimize immortal-time bias. Secondary outcomes were a composite vascular outcome (recurrent IS, transient ischemic attack (TIA), or vascular death) and recurrent IS/TIA; moderate-to-severe bleeding and intracranial hemorrhage (ICH) were assessed for safety. Inverse probability weighting (IPW) on a prespecified propensity score addressed confounding by indication, and weighted Cox models were fitted, with sensitivity analyses for the primary outcome.
Results
Among 1,442 patients discharged alive, 1,016 (70.5%) received statins at discharge. After weighting, propensity-score covariates were balanced. Over 90 days, statin therapy was associated with lower all-cause mortality (9.6% vs. 19.2%; HR 0.55, 95% CI 0.39-0.79). The composite vascular outcome showed a directionally similar but borderline association (HR 0.63, 95% CI 0.40-1.00); recurrent IS/TIA was not associated. Moderate-to-severe bleeding and ICH were rare and did not differ between groups. The mortality association was consistent across sensitivity analyses.
Conclusion
In AF patients with IS despite oral anticoagulation, statin therapy at discharge was associated with lower 90-day all-cause mortality, without increased short-term bleeding. Given the observational design, these hypothesis-generating findings support prospective evaluation of statins in this population.
Zitieren
APA
Merlino, G., Ornello, R., D’Anna, L., Gabriele, F., Zini, A., Paolucci, M., Forlivesi, S., Migliaccio, L., Viola, M. M., Rizzo, A. C., Sessa, M., Schwarz, G., Tortorella, R., Prandin, G., Banerjee, S., Desai, G., Pantoni, L., Mele, F., Scopelliti, G., …, & Spina, E. (2026). Beyond anticoagulation: Statin therapy and 90-day mortality after breakthrough ischemic stroke in atrial fibrillation. Therapeutic Advances in Neurological Disorders, 19. https://doi.org/10.1177/17562864261493716
Vancouver
Merlino G, Ornello R, D’Anna L, Gabriele F, Zini A, Paolucci M, et al. Beyond anticoagulation: Statin therapy and 90-day mortality after breakthrough ischemic stroke in atrial fibrillation. Therapeutic Advances in Neurological Disorders. 2026;19. doi:10.1177/17562864261493716
BibTeX
@article{Merlino2026,
author = {Merlino, Giovanni and Ornello, Raffaele and D’Anna, Lucio and Gabriele, Francesca and Zini, Andrea and Paolucci, Matteo and Forlivesi, Stefano and Migliaccio, Ludovica and Viola, Maria Maddalena and Rizzo, Angelo Cascio and Sessa, Maria and Schwarz, Ghil and Tortorella, Rachele and Prandin, Gabriele and Banerjee, Soma and Desai, Gurav and Pantoni, Leonardo and Mele, Francesco and Scopelliti, Giuseppe and Cova, Ilaria and Valente, Mariarosaria and Maisano, Domenico and Antonelli, Luca and Miele, Viviana and Bagnato, Maria Rosaria and Mauro, Giovanni Di and Bernocchi, Francesca and Donna, Martina Gaia Di and Casolla, Barbara and Bruno, Chiara and Alvarez, Baptiste and Souleymane-M-Bara, Diallo and González, Laura and Rigual, Ricardo and Fuentes, Blanca and Hervás, Carlos and Candelaresi, Paolo and Andreone, Vincenzo and Mase, Antonio De and Spina, Emanuele},
title = {Beyond anticoagulation: Statin therapy and 90-day mortality after breakthrough ischemic stroke in atrial fibrillation},
journal = {Therapeutic Advances in Neurological Disorders},
year = {2026},
volume = {19},
doi = {10.1177/17562864261493716}
}
EUVIMED